Qansy Salako
About
In The Last Decade
Qansy Salako
24 papers receiving 657 citations
Peers
Comparison fields: 5 of 61
- Radiology, Nuclear Medicine and Imaging 593
- Pathology and Forensic Medicine 212
- Pulmonary and Respiratory Medicine 167
- Oncology 167
- Molecular Biology 96
Countries citing papers authored by Qansy Salako
This map shows the geographic impact of Qansy Salako's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qansy Salako with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qansy Salako more than expected).
Fields of papers citing papers by Qansy Salako
This network shows the impact of papers produced by Qansy Salako. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qansy Salako. The network helps show where Qansy Salako may publish in the future.
Co-authorship network of co-authors of Qansy Salako
This figure shows the co-authorship network connecting the top 25 collaborators of Qansy Salako. A scholar is included among the top collaborators of Qansy Salako based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qansy Salako. Qansy Salako is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. | 55 |
| 2 | 146 | |
| 3 | Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. | 53 |
| 4 | Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. | 28 |
| 5 | Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. | 22 |
| 6 | Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. | 50 |
| 7 | 1 | |
| 8 | Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. | 69 |
| 9 | Radioassay of yttrium-90 radiation using the radionuclide dose calibrator. | 8 |
| 10 | Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy. | 17 |
| 11 | Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. | 10 |
| 12 | 55 | |
| 13 | 52 | |
| 14 | 9 | |
| 15 | 1 | |
| 16 | 1 | |
| 17 | 3 | |
| 18 | 5 | |
| 19 | Detection and determination of salicylic acid impurity in aspirin tablet formulations' by high performance liquid chromatography. | 4 |
| 20 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.